Northfield Laboratories Announces New Regulatory Leadership

Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that Richard D. Newman, Ph.D., D.A.B.T., will assume a leadership role for the Company in Regulatory Affairs. Dr. Newman has served as a consultant to Northfield on all aspects of regulatory matters since 2003. Eva Essig, Ph.D., who previously served in this role, has accepted a regulatory position in the pharmaceutical industry. "We have worked closely with Ric on regulatory affairs over the past four years and value the expertise he brings Northfield as we move forward in the regulatory process,” said Steven A. Gould, M.D., Chairman and Chief Executive Officer. Dr. Newman has substantial senior level management experience in regulatory and clinical affairs. He spent more than 25 years at Procter and Gamble, G.D. Searle, and Baxter Healthcare Corporation working on biologics, drugs and medical devices. At Baxter, Dr. Newman served in the Renal Division as Vice President from 1992-2002, beginning with Regulatory Affairs, and assuming increasing levels of responsibility for Clinical Affairs, and then Research and Development where he directed Global Product Development. About Northfield Laboratories Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. PolyHeme® is a solution of chemically modified human hemoglobin that requires no cross matching and is therefore compatible with all blood types. It has a shelf life in excess of 12 months. For further information, visit www.northfieldlabs.com. Forward Looking Statement This press release may contain forward-looking statements concerning, among other things, Northfield’s future business plans and strategies and clinical and regulatory developments affecting our PolyHeme red blood cell substitute product. These forward-looking statements are identified by the use of such terms as "intends,” "expects,” "plans,” "estimates,” "anticipates,” "should,” "believes” and similar terms. These forward-looking statements involve inherent risks and uncertainties. Our actual results may therefore differ materially from those predicted by the forward-looking statements because of various factors and possible events, including the possibility that since the data from our Phase III clinical trial have not been submitted to, or reviewed by, FDA, they may not be sufficient to demonstrate the safety or effectiveness of PolyHeme, our ability to obtain FDA approval to market PolyHeme commercially, our ability to obtain priority review, the availability of capital to finance our clinical trials and ongoing business operations, our ability to obtain adequate supplies of raw materials and to manufacture PolyHeme in commercial quantities, our ability to market PolyHeme successfully, the possibility that competitors will develop products that will render PolyHeme obsolete or non-competitive, our ability to protect our intellectual property rights, the outcome of certain governmental inquiries and purported class action lawsuit as described in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, the possibility that we may be subject to product liability claims and other legal actions, our dependency on a limited number of key personnel, the uncertainty of third party reimbursement for our product and other risks and uncertainties described from time to time in our periodic reports filed with the Securities and Exchange Commission, including our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. These forward-looking statements speak only as of the date of this press release. We do not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the time such statement is made. All subsequent written and oral forward-looking statements attributable to Northfield or any person acting on our behalf are qualified by this cautionary statement.